CUBIST PHARMACEUTICALS (CBST) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
CUBIST PHARMACEUTICALS (CBST)

An SI Board Since February 1997

Posts	SubjectMarks	Bans	Symbol
252	31	0	CBST

Emcee: Weekapaug	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
202	Where do I go to collect my prize for posting the 200th message??? And yes-Frank	telephonics	-	10/15/2007
201	Unfortunately and ironically, Frank Tally wasn't so lucky.	idos	-	10/14/2007
200	It's a good thing he succeeded. In the Metro Washington D.C. area there have	telephonics	-	10/13/2007
199	<b>An Antibiotic to the Rescue</b> How Cubist's Jeff Alder turne	idos	-	10/11/2007
198	>> Cubist Reveals Drug Patent Error By Elizabeth Trotta Staff Reporter 9/1	tuck	-	9/13/2007
197	Cubicin recommended for endocarditis in the EU: Message 23716289 Near the bott	tuck	-	7/19/2007
196	The company is now profitable and because the wall street sages guessed wrong th	telephonics	-	4/19/2007
195	CBST earnins in line, no guidance in PR: >>Cubist Pharmaceuticals Reports	tuck	-	4/18/2007
194	[Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a un	tuck	-	1/25/2007
193	CBST reported fourth-quarter results below analysts' estimates and said it e	idos	-	1/25/2007
192	Revenue guidance given as 255 - 270 million . Consensus is $279, so this is a b	tuck	-	1/24/2007
191	>>Cubist Pharmaceuticals Reports GAAP Basic Net Income of $0.10 Per Share	tuck	-	1/24/2007
190	>>Fourth Quarter 2006 U.S. Net Product Revenues of $56.2 Million and Full	tuck	-	1/8/2007
189	marketwatch.com Cubist: Fourth-quarter U.S. Cubicin revenue up 54% By Gabriel M	idos	-	1/8/2007
188	Merrill: Lowering 2007 estimates and price objective to $27 We are lowering our	tom pope	-	1/8/2007
187	I was wondering that, too, but THRX hasn't budged for a month, and it's	tuck	-	12/11/2006
186	Wonder whether it has anything to do with thrx, telavancin, just filed their nda	rkrw	-	12/10/2006
185	Yeah i read it. thanks for linking. special thanks to Tom for replaying. best,	idos	-	12/9/2006
184	Tom is going to hound ML for us. He was kind enough to post their most recent n	tuck	-	12/8/2006
183	Even if they don't defend CBST, i'm in because i don't see anything	idos	-	12/8/2006
182	Yeah, I doubled down in spite of my worries about it breaking down here. I have	tuck	-	12/8/2006
181	agreed, quite strange this downgrade. can't say much except it is an entry p	idos	-	12/8/2006
180	From outperform to market perform with a target of $23. Don't know what the	tuck	-	12/8/2006
179	CBST was downgraded today by Piper Jaffray and the stock is down some 5%.	idos	-	12/8/2006
178	Merrill Cubist Pharmaceuticals Inc Estimate Change; 3Q Cubicin seasonally lig	tom pope	-	10/19/2006

Go to reply# or date (mm/dd/yy):